Deze week: ortheses (brace of spalk) voor hallux valgus (voetknobbel ... “Op de website van Epitact, een bekend merk, tonen ze beelden van de situatie met en zonder orthese.

De echtgenoot van kroonprinses Victoria draagt sinds februari een spalk met verband om de bewuste vinger, ontdekte Expressen. Het hof wil niet reageren op vragen van de Zweedse krant en zegt dat ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China. The estimate doesn’t account for the possibility that ...

The player in question here is Abby Merk who is being brought on as an official BetMGM Poker ambassador and content partner. Merk, who is both a pro poker player and content creator, will ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous challenges plaguing the company resulted in the dilution of the stock ...

One of Merck KGaA’s leading immunology assets has flunked the latest part of a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded further development is warranted in ...

While most memecoins rely on short-term speculation, MERK is redefining the landscape with an AI-driven ecosystem that merges blockchain innovation, automation, and sustainable tokenomics.

Dr. James Albert Merk, M.D., a dedicated husband, father, grandfather, great-grandfather, and revered Lancaster family physician, passed away on February 5 at the age of 93. Born in Cincinnati on ...

The company's key drug, Gardasil, is facing slowing sales in China. Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly beat ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 10% in early trading, largely because of weaker ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF ...